+34 620 10 75 37info@nanbiosis.com
In vivo ADME and biodistribution assays
Accessories:
In this interview, Jaume Veciana assesses the functioning of this Singular Scientific-Technical Infrastructure and its contribution to research and anticipates some of the guidelines of the NANBIOSIS Strategic Plan 2017-2020, which includes a clear commitment to internationalization.
“The scientific-technical capabilities available at NANBIOSIS must be exploited without limitation to our country. Therefore we are clear that we must promote the activity of NANBIOSIS both academic and industrial sector in the European Union and other countries, either directly or in association with other similar organizations actions. Some such initiatives have already started but we believe it should be given further boost to internationalization. As an example we can mention the participation in the European project INFRAIA that aims to integrate regional and national research infrastructures existing in Europe under the Horizon 2020”
Professor Veciana also talks about NANOMOL, the research group coordinator of Unit 6 of NANBIOSIS, and the main applications of their findings in the fields of nanomedicine and biomaterials.
The objectives of ESNAM are to promote nanomedicine research and facilitate the exchange of knowledge among its members (currently, about 800 members). According to Dr. Simó Schwartz “the dissemination of specialized infrastructure in nanomedicine, like NANBIOSIS, among members of the society and its utilities is also an object of ESNAM. This is intended to strengthen European technological capabilities, use, and improvement of clinical transfer”.
Society members represent different sectors of the scientific community: doctors, biologists, chemists, pharmacists, physical …. The technical office of the ESNAM in Barcelona is located in the Vall d’Hebron Hospital and is coordinated by Aida Castellanos, CIBER-BBN R&D+i Project Manager.
In addition, Dr. Schwartz has also been appointed a member of the executive board of the International Society of Nanomedicine (ISN), a newly established company that includes the American Association, Korean and European, ESNAM, among others. This entity will organize the 2nd year of summer in Barcelona Nanomedicine 2017, this year held in South Korea.
RADAR-CNS is an important European research program supported by the Innovative Medicines Initiative (IMI) focused to develop new ways of monitoring patients affected by major depression, epilepsy and multiple sclerosis, with the use of wearable technology and smart mobile phones.
This program brings together experts from various disciplines in clinical research, engineering, computer and data analysis, as well as health services. RADAR-CN aims to improve symptoms and quality of life of patients and treatment of these and other chronic diseases. This program is jointly led by King’s College London and the pharmaceutical company Janssen and is funded by the Innovative Medicines Initiative (a public-private agreement EFPIA and the European Union). RADAR-CNS involves 24 organizations in Europe and US, including CIBER through its thematic areas of Mental Health (CIBERSAM) and Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN)
“In recent years, the quality and quantity of data that can be collected with the wearable technology and smart phones has increased a lot. The information generated with this large amount of data will help to improve clinical care by providing greater detail of the patient’s condition and prognosis of its evolution. Moreover, it will be possible to detect whether a patient is beginning to have problems before there is clinical evidence of it” says Dr. Jordi Aguilo, scientific coordinator of the Unit 8 of NANBIOSIS.
This huge generate data sets, suitable to be stored and treated so to retrieve the relevant information hidden in the data, frequently require computing systems and information systems of high performance. The Unit 27 of NANBIOSIS will be the platform in which this analysis will be performed.
